Granules India gets USFDA nod for generic drug used for short-term treatment of heartburn
Granules India has received approval from the US Food & Drug Administration (USFDA) for its generic Esomeprazole Magnesium delayed-release capsules. The capsules are used for the short-term treatment of heartburn and other symptoms of gastroesophageal reflux disease. The approval is for capsules with strengths of 20 mg and 40 mg, and they are bioequivalent and therapeutically equivalent to the reference drug, Nexium. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 19, 2023 Category: Pharmaceuticals Source Type: news

$425M Heartburn Drug Settlement; 5 Years for Clinic Fire; $2.5M Broken Leg Award
(MedPage Today) -- AstraZeneca will pay $425 million to settle lawsuits alleging that patients suffered kidney injuries while using its heartburn drugs esomeprazole (Nexium) and omeprazole (Prilosec). (The Hill) A 22-year-old woman was sentenced... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 5, 2023 Category: American Health Source Type: news

AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million
The payout will settle the claims of 11,000 people who said they weren ’t property warned Nexium and Prilosec could cause chronic kidney disease. (Source: Healthcare News)
Source: Healthcare News - October 3, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news

Fast Heartburn Relief Without Deadly Drugs
Since gastroesophageal reflux disease (GERD) was first identified in the early 1930s, the number of people experiencing heartburn has increased substantially. In fact, one study shows that in just 10 years, the number of people experiencing:1 Any GERD symptoms increased by 30% Symptoms at least once a week increased by 47% Severe GERD increased by 24% While these numbers are concerning, I’ll admit they’re not surprising considering the typical American diet. Our nutrition-less, grain-based diet of carbohydrates and starches has wrecked our health and made our bodies behave in ways nature never intended. This has led ...
Source: Al Sears, MD Natural Remedies - August 28, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Heart Health Natural Cures Nutrition Source Type: news

Class 4 Medicines Defect Information: Esomeprazole 40mg Powder for Solution for Injection/Infusion
DEMO SA PHARMACEUTICAL INDUSTRY has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the Product Code/GTIN (PC) number found on a specific batch of Esomeprazole 40mg Powder (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - May 31, 2022 Category: Drugs & Pharmacology Source Type: news

Vimovo (naproxen and esomeprazole magnesium)
Title: Vimovo (naproxen and esomeprazole magnesium)Category: MedicationsCreated: 5/12/2021 12:00:00 AMLast Editorial Review: 5/12/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 12, 2021 Category: Rheumatology Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cipla recalls over 5.8 lakh packets of gastric ulcer treatment drug in US
The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market, the latest Enforcement Report by the USFDA said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2021 Category: Pharmaceuticals Source Type: news

Common Heartburn Drugs May Be Tied to Higher COVID Risk
TUESDAY, July 14, 2020 -- Popular heartburn medications such as Prilosec (omeprazole) and Nexium (esomeprazole) may inadvertently up your chances of catching COVID-19, new research suggests. An online survey of more than 53,000 Americans, all with a... (Source: - Daily MedNews)
Source: - Daily MedNews - July 14, 2020 Category: General Medicine Source Type: news

Taste disorder ’s management: a systematic review
ConclusionImproving oral hygiene may promote taste ability. Zinc may prevent and alleviate taste disorder in patients undergoing head and neck radiotherapy.Clinical relevanceThe systematic review provided evidence about the clinical efficacy of oral procedures, zinc supplementation, and palliative cares in dysgeusic patients. Further research is needed to find effective treatments with low adverse effects. (Source: Dental Technology Blog)
Source: Dental Technology Blog - May 14, 2020 Category: Dentistry Source Type: news

FDA Calls For Heartburn Drug Zantac To Be Pulled From Market Immediately
(CNN) — The US Food and Drug Administration is requesting that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately, the agency announced on Wednesday. The FDA noted that an ongoing investigation has determined that levels of a contaminant in the heartburn medications increase over time and when stored at higher-than-normal temperatures, poses a risk to public health. The contaminant, N-nitrosodimethylamine or NDMA, is a probable human carcinogen and the FDA has been investigating levels of it in ranitidine since the summer of 2019. ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 1, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Zantac Source Type: news

Cipla Receives Final Approval for Generic Version of AstraZeneca Pharmaceutical's Nexium(R) (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg)
Cipla is the first company to file for the 10mg strength MUMBAI, India, March 27, 2020 -- (Healthcare Sales & Marketing Network) -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") today announced that it has ... Biopharmaceuticals, Generics, FDA Cipla, Esomeprazole, Nexium, AstraZeneca (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2020 Category: Pharmaceuticals Source Type: news

Cipla gets USFDA nod for generic acid reflux drug
The company has received final approval for its abbreviated new drug application (ANDA) for Esomeprazole for oral suspension in the strengths of 10mg, 20mg and 40mg from the United States Food and Drug Administration (USFDA), Cipla said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 25, 2020 Category: Pharmaceuticals Source Type: news

Could Heartburn Meds Lead to Drug-Resistant Germs?
The findings do not prove that PPIs -- which include popular brands such as Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole) -- are the cause, experts said.         But they are the latest to raise safety questions about the top-selling prescription and over-the-counter medicines. (Source: WebMD Health)
Source: WebMD Health - February 25, 2020 Category: Consumer Health News Source Type: news

Sun Pharma gets partial relief from US court in litigation involving three generic drugs
Drug major Sun Pharma is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole. The company said it would continue to vigorously defend against all claims. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2019 Category: Pharmaceuticals Source Type: news